MAPT and Alzheimer disease: These findings suggest that pharmacologic activation of Nrf2 could be a promising therapeutic strategy to delay the onset of AD, slow disease progression by targeting tau pathology through enhanced autophagic clearance mechanisms, and attenuate cognitive dysfunction [41].